GlassScriptPhysician profile
Kim Mccullough
NPI 1174970487
$859.43
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $831 · 2022: $28.93.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $223.33 | 2021 | |
| Abbvie INC. | $140.16 | 2021 | |
| Electromed, INC. | $76.53 | 2021-2022 | |
| Insulet Corporation | $75.01 | 2021 | |
| Mylan Specialty L.P. | $54.91 | 2021 | |
| Glaxosmithkline, LLC. | $53.28 | 2021 | |
| Vanda Pharmaceuticals INC. | $36.96 | 2021 | |
| Lilly USA, LLC | $33.37 | 2021 | |
| Pfizer INC. | $29.96 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $17.37 | 2021 | |
| Dexcom, INC. | $16.79 | 2021 | |
| Sanofi-Aventis U.S. LLC | $15.14 | 2021 | |
| Astellas Pharma US INC | $14.37 | 2021 | |
| Janssen Pharmaceuticals, INC | $13.39 | 2021 | |
| Lundbeck LLC | $12.62 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $11.96 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $11.81 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.29 | 2021 | |
| Amgen INC. | $11.18 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kim Mccullough listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.